Eglin Pharma Recognized as One of China's Most Promising Seed Enterprises in 2022
On September 15, the results of the “EY-Fudan Most Promising Enterprises 2022” awards were officially announced in Shanghai. Aeglea Pharma ultimately stood out from a large pool of candidates after rigorous screening, thanks to its core founding and management team composed of FDA review experts with extensive experience in new drug development, its clinical R&D and AI/quantum technology teams assembled with top-tier talent, its differentiated R&D and business models, and the efficient development of its pipeline.Featured on the 2026 “EY-Fudan Most Promising Companies” List。
Award Ceremony Venue
From eight major industries, a total of 32 companies were selected for the Most Promising Companies and Seed Enterprise Awards., the shortlisted emerging enterprises primarily span virtual reality, chips, robotics/automation systems, cloud computing/digitalization, new energy, mobility, healthcare, and retail. As a representative innovative pharmaceutical company, Eglin Pharma has always adhered to its mission of “focusing on clinical needs, realizing pharmaceutical value, and benefiting patients worldwide.” Leveraging “end-to-end” artificial intelligence and quantum computing as core technologies, the company develops first-in-class drugs that address urgent global clinical needs through source innovation, significantly improving the efficiency and success rate of drug R&D. The company focuses on drug development in the fields of immunology (including tumor immunity) and ophthalmology, achieving rapid growth. Within just three years of its establishment, five out of ten pipeline candidates have received clinical trial approval from the U.S. FDA. Notably, the R&D efficiency of AI/quantum-assisted drugs, represented by EG-301, has been substantially enhanced, with the progression from preclinical stages to Phase II clinical trials taking less than 18 months.
Dr. Du Tao, Chairman of Eglin Pharma, and Ms. Yang Yihang, Chief Financial Officer
As a globally leading professional services organization, EY China has partnered with the School of Management at Fudan University, a top-tier Chinese academic institution, to host the “Most Promising Enterprises” awards for twelve consecutive years. Adhering to the principles of professionalism, objectivity, and transparency, the program evaluates the comprehensive strength of promising enterprises based on criteria such as future growth potential, sustainability, national and international development, and distinct competitive advantages. Experts on the judging panel believe that the award-winning companies represent exemplary models of creativity and innovative spirit in today’s business world, and will further provide new momentum for boosting China’s high-level self-reliance and strength in science and technology, helping it join the ranks of the world’s leading technological powers. This marks another prestigious award for Eaglerise Pharmaceutical, following its inclusion in this year’s VB100 “Top 100 Innovative Biopharmaceutical Companies.” This recognition undoubtedly reaffirms the industry’s endorsement of the company’s value.
Shenzhen Aigelin Pharmaceutical Co., Ltd. is an international innovative pharmaceutical company centered on AI technology. The company maintains offices and laboratories in both Shenzhen, China, and Maryland, USA, and boasts a cross-disciplinary team of top-tier professionals specializing in clinical medicine, computational science, chemistry, pharmacology/toxicology, and FDA regulatory affairs. It focuses on the discovery and development of innovative drugs in ophthalmology and immunology (including tumor immunology), as well as efficient global clinical development and commercialization. Additionally, Aigelin Pharmaceutical provides partners with various development services, international development solutions, and high-end regulatory affairs services. The company’s growth has been widely recognized by the industry; it has been listed among the “Top 100 Seed Enterprises for Pharmaceutical Innovation in China” and the “Top 100 Innovative Biopharmaceutical Companies” for two consecutive years, and was named one of Ernst & Young and Fudan University’s Most Promising Enterprises, regarded as a rising star poised to become a pillar of the national industry.